2 citations
,
January 2016 in “UvA-DARE (University of Amsterdam)” This review explores the unclear rationale behind excluding medical treatment methods from patentability and the complexities of allowing medical indication patents, offering potential solutions but reporting no new results.
February 2011 in “Journal of Intellectual Property Law & Practice” This article reviews the conflicting approaches to patentability of dosage regimen inventions under Chinese law and reports no resolution on which position Chinese courts will adopt.
7 citations
,
April 2017 in “Health Economics, Policy and Law” This review analyzes current patent trends in personalized medicine, suggesting they often privilege the pharmaceutical industry without adequately demonstrating overall public benefit.
January 2014 in “Elsevier eBooks” This chapter discusses the process from ideation to patent and licensure for biotechnologies, offering an introduction to the intersection of business, law, and biotechnology without reporting new results.
1 citations
,
April 2009 in “Journal of Intellectual Property Law & Practice” This review discusses the legal status of patents for treatment and dosage regimes under the Patents Act 1977 and EPC 2000, highlighting ongoing uncertainties in their availability.